The Food and Drug Administration has granted approval for the next-generation anticlotting medication Eliquis, the regulator announced in a news release. The drug, administered in the form of a pill, is used to reduce stroke risk and fight clotting in patients with atrial fibrillation. This is a common variety of abnormal heart rhythm.

Eliquis has been developed jointly by Pfizer (NYS: PFE) and Bristol-Myers Squibb (NYS: BMY) .

The new drug is seen as a replacement for wafarin, the current standard treatment for the disorder. It is difficult to determine the precise dose for wafarin, however, and the side effects can be extreme. 


It is estimated that over 3 million people in the U.S. and around 8 million throughout the world suffer from atrial fibrillation. It is one of the top causes of stroke. 

The article FDA Clears Anticlotting Drug Eliquis originally appeared on Fool.com.

Eric Volkman has no positions in the stocks mentioned above, and neither does The Motley Fool. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 - 2012 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.


Increase your money and finance knowledge from home

Finding Stock Ideas

Learn to do your research and find investments.

View Course »

Basics Of The Stock Market

Stock Market 101 - everything you need to know but were afraid to ask!

View Course »

Add a Comment

*0 / 3000 Character Maximum